Header Logo

Connection

KENNETH R HESS to Breast Neoplasms

Back to Details
This is a "connection" page, showing publications KENNETH R HESS has written about Breast Neoplasms.
KENNETH R HESS
Connection Strength
1.387
Breast Neoplasms
  1. Effect of HER2 status on distant recurrence in early stage breast cancer. Breast Cancer Res Treat. 2013 Jan; 137(2):449-55.
    View in: PubMed
    Score: 0.080
  2. Lack of sufficiently strong informative features limits the potential of gene expression analysis as predictive tool for many clinical classification problems. BMC Bioinformatics. 2011 Dec 01; 12:463.
    View in: PubMed
    Score: 0.075
  3. Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer. Clin Cancer Res. 2007 Oct 15; 13(20):6080-6.
    View in: PubMed
    Score: 0.056
  4. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006 Sep 10; 24(26):4236-44.
    View in: PubMed
    Score: 0.052
  5. Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat. 2003 Mar; 78(1):105-18.
    View in: PubMed
    Score: 0.041
  6. Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Breast Cancer Res Treat. 2021 Jan; 185(1):1-12.
    View in: PubMed
    Score: 0.034
  7. Central nervous system miliary metastasis in breast cancer: a case series analysis and proposed identification criteria of a rare metastasis subtype. Br J Cancer. 2020 10; 123(9):1417-1423.
    View in: PubMed
    Score: 0.034
  8. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. BMC Cancer. 2020 May 18; 20(1):430.
    View in: PubMed
    Score: 0.034
  9. The role of magnetic resonance imaging in patients with palpable breast abnormalities and negative mammographic and sonographic findings. Breast J. 2020 07; 26(7):1289-1295.
    View in: PubMed
    Score: 0.033
  10. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol. 2020 02 10; 38(5):388-394.
    View in: PubMed
    Score: 0.032
  11. Variation in Technical Quality of Breast MRI. Acad Radiol. 2020 04; 27(4):468-475.
    View in: PubMed
    Score: 0.032
  12. Imaging Follow-up Versus Surgical Excision for Radial Scars Identified on Tomosynthesis-Guided Core Needle Biopsy. Acad Radiol. 2020 03; 27(3):389-394.
    View in: PubMed
    Score: 0.032
  13. Immediate Migration of Biopsy Clip Markers After Upright Digital Breast Tomosynthesis-Guided Vacuum-Assisted Core Biopsy. Acad Radiol. 2020 02; 27(2):204-209.
    View in: PubMed
    Score: 0.031
  14. Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1). Breast Cancer Res Treat. 2019 Jul; 176(1):227-234.
    View in: PubMed
    Score: 0.031
  15. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. Invest New Drugs. 2019 04; 37(2):345-351.
    View in: PubMed
    Score: 0.030
  16. Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clin Breast Cancer. 2018 12; 18(6):e1283-e1288.
    View in: PubMed
    Score: 0.029
  17. High risk breast lesions identified on MRI-guided vacuum-assisted?needle?biopsy: outcome of surgical excision and imaging follow-up. Br J Radiol. 2018 Oct; 91(1090):20180300.
    View in: PubMed
    Score: 0.029
  18. Imaging of Intracystic Papillary Carcinoma. Curr Probl Diagn Radiol. 2019 Jul - Aug; 48(4):348-352.
    View in: PubMed
    Score: 0.029
  19. Comparison of Residual Risk-Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies. JAMA Oncol. 2018 Apr 12; 4(4):e175092.
    View in: PubMed
    Score: 0.029
  20. Effect of Mammography on Marker Clip Migration After Stereotactic-Guided Core Needle Breast Biopsy. Curr Probl Diagn Radiol. 2017 Nov - Dec; 46(6):410-414.
    View in: PubMed
    Score: 0.027
  21. Imaging-Concordant Benign MRI-Guided Vacuum-Assisted Breast Biopsy May Not Warrant MRI Follow-Up. AJR Am J Roentgenol. 2017 Apr; 208(4):916-922.
    View in: PubMed
    Score: 0.027
  22. Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study. Cancer. 2017 04 01; 123(7):1115-1123.
    View in: PubMed
    Score: 0.026
  23. Incidental Suspicious Regional Lymph Nodes on Breast Sonography: Is Sampling Necessary? Curr Probl Diagn Radiol. 2017 Mar - Apr; 46(2):100-104.
    View in: PubMed
    Score: 0.025
  24. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2016 Mar 20; 34(9):945-52.
    View in: PubMed
    Score: 0.025
  25. Development of a model to predict breast cancer survival using data from the National Cancer Data Base. Surgery. 2016 Feb; 159(2):495-502.
    View in: PubMed
    Score: 0.024
  26. Reproducibility of Variant Calls in Replicate Next Generation Sequencing Experiments. PLoS One. 2015; 10(7):e0119230.
    View in: PubMed
    Score: 0.024
  27. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. Oncologist. 2015 May; 20(5):466-73.
    View in: PubMed
    Score: 0.023
  28. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer. 2014 Jul 01; 120(13):1932-8.
    View in: PubMed
    Score: 0.022
  29. Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab. Oncologist. 2014 Mar; 19(3):228-34.
    View in: PubMed
    Score: 0.022
  30. Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients. Cancer. 1993 Oct 01; 72(7):2291-2.
    View in: PubMed
    Score: 0.021
  31. Human endogenous retrovirus type K antibodies and mRNA as serum biomarkers of early-stage breast cancer. Int J Cancer. 2014 Feb 01; 134(3):587-95.
    View in: PubMed
    Score: 0.021
  32. The prognostic impact of age in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2013 Apr; 138(2):591-9.
    View in: PubMed
    Score: 0.020
  33. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat. 2013 Jan; 137(2):631-6.
    View in: PubMed
    Score: 0.020
  34. Systematic analysis of in vitro chemosensitivity and mib-1 expression in molecular breast cancer subtypes. Eur J Cancer. 2012 Sep; 48(13):2066-74.
    View in: PubMed
    Score: 0.018
  35. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 2011 Jun 15; 13(3):R67.
    View in: PubMed
    Score: 0.018
  36. Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold? Ann Oncol. 2011 Nov; 22(11):2387-2393.
    View in: PubMed
    Score: 0.018
  37. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res. 2010 Nov 01; 16(21):5351-61.
    View in: PubMed
    Score: 0.017
  38. Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. Mol Cancer Ther. 2010 May; 9(5):1120-7.
    View in: PubMed
    Score: 0.017
  39. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res. 2010; 12(1):R5.
    View in: PubMed
    Score: 0.016
  40. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol. 2009 Sep; 94(2):229-34.
    View in: PubMed
    Score: 0.015
  41. Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat. 2010 Jan; 119(2):305-14.
    View in: PubMed
    Score: 0.015
  42. Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer. J Clin Oncol. 2008 Oct 01; 26(28):4679-83.
    View in: PubMed
    Score: 0.015
  43. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008 Mar 10; 26(8):1275-81.
    View in: PubMed
    Score: 0.014
  44. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol. 2007 Mar; 8(3):203-11.
    View in: PubMed
    Score: 0.013
  45. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol. 2006 Sep 01; 24(25):4107-15.
    View in: PubMed
    Score: 0.013
  46. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol. 2005 Nov 20; 23(33):8331-9.
    View in: PubMed
    Score: 0.012
  47. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005 Aug 15; 11(16):5678-85.
    View in: PubMed
    Score: 0.012
  48. Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChips. J Mol Diagn. 2005 Aug; 7(3):357-67.
    View in: PubMed
    Score: 0.012
  49. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A. 2005 Jun 07; 102(23):8315-20.
    View in: PubMed
    Score: 0.012
  50. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004 Jun 15; 22(12):2284-93.
    View in: PubMed
    Score: 0.011
  51. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res. 2003 Jul; 9(7):2406-15.
    View in: PubMed
    Score: 0.010
  52. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer. 2003 Jun 15; 97(12):2960-71.
    View in: PubMed
    Score: 0.010
  53. Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response. Clin Cancer Res. 2003 Mar; 9(3):955-60.
    View in: PubMed
    Score: 0.010
  54. Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J. 2002 Nov-Dec; 8(6):461-8.
    View in: PubMed
    Score: 0.010
  55. Not all patients with a diagnosis of a radial scar require excision. Breast J. 2019 07; 25(4):792-794.
    View in: PubMed
    Score: 0.008
  56. Effect of pregnancy on prognosis for young women with breast cancer. Lancet. 1994 Jun 25; 343(8913):1587-9.
    View in: PubMed
    Score: 0.006
  57. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol. 2010 Aug; 28(8):827-38.
    View in: PubMed
    Score: 0.004
  58. Reproducibility of gene expression signature-based predictions in replicate experiments. Clin Cancer Res. 2006 Mar 15; 12(6):1721-7.
    View in: PubMed
    Score: 0.003
  59. TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J Clin Oncol. 1997 Mar; 15(3):1063-70.
    View in: PubMed
    Score: 0.002
  60. Reoperation for recurrent metastatic brain tumors. J Neurosurg. 1995 Oct; 83(4):600-4.
    View in: PubMed
    Score: 0.002
  61. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol. 1995 Aug; 13(8):2094-103.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.